Navigation Links
QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
Date:10/25/2012

HILDEN, Germany, October 25, 2012 /PRNewswire/ --

  • QIAGEN and Bayer HealthCare signed collaboration agreement aimed at advancing both companies positions in personalized medicine
  • The programs pair QIAGEN companion diagnostic solutions with innovative targeted therapies for patients with solid tumors developed by Bayer HealthCare
  • Agreement provides framework for further collaboration projects

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information from each patient's tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. Financial details were not disclosed.

The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.

"We are very pleased to partner with Bayer HealthCare in developing companion diagnostics to improve life for cancer patients. As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. "The first collaborations for Bayer HealthCare and QIAGEN include companion diagnostics ba
'/>"/>

SOURCE Qiagen N V
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
2. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
5. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
6. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
7. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
8. AspenBio to Present at 2012 Aegis Healthcare Conference
9. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
10. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
11. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... AMES, Iowa - Researchers at the U.S. Department ... a potentially perfect way to sort and distribute ... over optical fibers to people ,throughout the world. ... filter, promises greatly enhanced transmission of multiple ,wavelength ...
... Feb. 18 - Biotech pioneer,William J. Rutter, PhD, ... RAPS,Horizons Conference & Exhibition in San Francisco next ... Rutter, Chairman and CEO of Synergenics LLC ... fresh and relevant perspectives on,the regulatory implications of ...
... 18 JADO Technologies GmbH,the leading developer of ... Phase IIa clinical trial of its lead RAFT ... a topical,formulation of miltefosine, exerts its anti- inflammatory ... lipid membrane of cells that,play a role in ...
Cached Biology Technology:New filter clears up fiber optic communications 2New filter clears up fiber optic communications 3Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 3
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market ... Report: The Convergence of Commerce and Privacy" forecasts ... mobile biometric apps will be downloaded to smart ... The mobile biometrics market is projected to generate ... revenue during the seven-year forecast period.    ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... science takes a giant leap forward with a new ... new $1.5 million per year Pedo-Biometrics Research and Identity ... Ottawa, Canada, company currently relocating operations to the U.S., ... of identification uses, from security to detecting the onset ...
... Santa Barbara, Calif. As spatial planning is used increasingly ... to determine the best ways to use and refine the ... (MPAs), one of the most common methods, which limit or ... paper published in the early edition of the Proceedings ...
... Technology (Caltech) pioneered the study of the link ... disorders such as autism a decade ago. Since ... with autism, as well as epidemiological studies, have ... system and autism spectrum disorder. What has ...
Cached Biology News:Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 2Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 3Refining the tool kit for sustainable fisheries 2Refining the tool kit for sustainable fisheries 3Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3
...
...
... Transfer Vector is a derivative of the pAcHLT-A ... blue fluorescent protein (BFP), followed by a 6xHis ... are expressed as BFP-6xHis fusion proteins when cloned ... I, Stu I, Sac I, Not I, Pst ...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: